^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A prospective, open-label, one-arm clinical study of pemetrexed in combination with platinum-based regimens in patients with advanced non-squamous non-small cell lung cancer treated with apatinib after 4-6 cycles of chemotherapy
Excerpt:
...If the genetic test (EGFR/ALK) is an EGFR-sensitive mutation or an ALK fusion gene-positive patient, it is necessary to receive targeted therapy for the first-line treatment; if there is no mutation, it is necessary to be a first-line patient; 4. ...
Trial ID:
Source:
Title:
A prospective, real-world clinical study of the efficacy and safety of camrelizumab combined with pemetrexed and bevacizumab in the treatment of newly diagnosed driver-gene-negative advanced non-squamous non-small cell lung cancer
Excerpt:
...The subjects with negative driving gene (EGFR mutation, ALK fusion mutation, c-Met amplification and ros-1 mutation) were confirmed by Histocytology; 7. ...
Trial ID:
Less C2 evidence
Source:
Title:
Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.
Published date:
05/19/2021
Excerpt:
...28 ALK positive NSCLC patients who had received pemetrexed-based chemotherapy...OS from pemetrexed-based chemotherapy of ALK-TKI treated group was also significantly shorter than ALK-naïve group...Pemetrexed-based chemotherapy might be less effective in ALK-positive NSCLC patients previously treated with ALK-TKI.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2021.39.15_suppl.e21113
